Sellas Life Sciences Group Inc (NASDAQ:SLS) — Market Cap & Net Worth
Market Cap & Net Worth: Sellas Life Sciences Group Inc (SLS)
Sellas Life Sciences Group Inc (NASDAQ:SLS) has a market capitalization of $968.80 Million ($968.80 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8900 globally and #2527 in its home market, demonstrating a -18.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sellas Life Sciences Group Inc's stock price $10.01 by its total outstanding shares 184532574 (184.53 Million). Review SLS cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
Sellas Life Sciences Group Inc Market Cap History: 2015 to 2026
Sellas Life Sciences Group Inc's market capitalization history from 2015 to 2026. Data shows change from $8.14 Trillion to $1.85 Billion (-54.72% CAGR).
Index Memberships
Sellas Life Sciences Group Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.04% | #258 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #961 of 3165 |
Weight: Sellas Life Sciences Group Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sellas Life Sciences Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sellas Life Sciences Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
435.50x
Sellas Life Sciences Group Inc's market cap is 435.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.07 Billion | $1.90K | -$16.76 Million | 564281.19x | N/A |
| 2021 | $1.02 Billion | $7.60 Million | -$20.70 Million | 134.27x | N/A |
| 2022 | $435.50 Million | $1.00 Million | -$41.30 Million | 435.50x | N/A |
Competitor Companies of SLS by Market Capitalization
Companies near Sellas Life Sciences Group Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Sellas Life Sciences Group Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Sellas Life Sciences Group Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sellas Life Sciences Group Inc's market cap moved from $8.14 Trillion to $ 1.85 Billion, with a yearly change of -54.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.85 Billion | +165.52% |
| 2025 | $695.69 Million | +262.50% |
| 2024 | $191.91 Million | -1.89% |
| 2023 | $195.60 Million | -55.08% |
| 2022 | $435.50 Million | -57.32% |
| 2021 | $1.02 Billion | -4.82% |
| 2020 | $1.07 Billion | +35.12% |
| 2019 | $793.49 Million | -93.01% |
| 2018 | $11.35 Billion | -84.35% |
| 2017 | $72.52 Billion | -86.49% |
| 2016 | $536.99 Billion | -93.40% |
| 2015 | $8.14 Trillion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Sellas Life Sciences Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $968.80 Million USD |
| MoneyControl | $968.80 Million USD |
| MarketWatch | $968.80 Million USD |
| marketcap.company | $968.80 Million USD |
| Reuters | $968.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more